思创医惠8月18日晚间发布公告称，公司董事会于近日收到公司副总经理华松鸳女士提交的书面辞职报 告，华松鸳女士因个人职业规划原因申请辞去公司副总经理职务，辞职后不再担任公司任何职务。华松 鸳女士的辞职报告自送达董事会之日起生效。 （文章来源：每日经济新闻） ...

证券代码：300078 证券简称：思创医惠 公告编号：2025-088 思创医惠科技股份有限公司 关于公司副总经理辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 思创医惠科技股份有限公司（以下简称"公司"）董事会于近日收到公司副 总经理华松鸳女士提交的书面辞职报告，华松鸳女士因个人职业规划原因申请辞 去公司副总经理职务，辞职后不再担任公司任何职务。根据《中华人民共和国公 司法》及《公司章程》等有关规定，华松鸳女士的辞职报告自送达董事会之日起 生效。华松鸳女士原定任期为 2024 年 12 月 6 日至 2027 年 12 月 5 日。 截至本公告披露日，华松鸳女士未直接或间接持有公司股份，且不存在应履 行而未履行的承诺，辞职不会影响公司相关工作的正常进行。华松鸳女士辞职后， 在原定任期及任期届满后六个月内仍将继续遵守《上市公司股东减持股份管理暂 行办法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》《深 圳证券交易所上市公司自律监管指引第 18 号——股东及董事、高级管理人员减 持股份》等相关法律法规对任期届满前离任高级管理人员股份转 ...

浙江证监局指出，思创医惠时任董事长、总经理章笠中违法情节严重，该局拟决定：对章笠中采取10年 市场禁入措施。自浙江证监局宣布决定之日起，在禁入期间内，除不得继续在原机构从事证券业务或者 担任原上市公司、非上市公众公司董事、监事、高级管理人员职务外，也不得在其他任何机构中从事证 券业务或者担任其他上市公司、非上市公众公司董事、监事、高级管理人员职务。 中国经济网北京8月18日讯思创医惠（300078）(300078.SZ)15日发布关于收到杭州市公安局调取证据通 知书的公告。2025年8月14日，思创医惠收到杭州市公安局出具给公司的《调取证据通知书》【杭公 (经)调证字[2025]00481号】。《调取证据通知书》显示，杭州市公安局侦办的公司等涉嫌欺诈发行证券 案需调取公司有关证据材料。 截至目前，上述案件尚处于公安机关侦查阶段，尚未有明确结论。公司将积极配合公安机关的调查取证 工作。 思创医惠2023年9月发布公告称，公司于2023年9月25日收到中国证券监督管理委员会浙江监管局下发的 《行政处罚及市场禁入事先告知书》(浙处罚字[2023]28号)。 思创医惠涉嫌欺诈发行及信息披露违法违规一案，已由浙江证监局 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 思创医惠（维权）(300078.SZ)盘初一度跌逾15%，现跌10.33%报3.56元，总市值不足40亿元。思创医惠公告称，公司于2025年8月14日收到杭州市公安局出 具的《调取证据通知书》，《调取证据通知书》显示，杭州市公安局侦办的公司等涉嫌欺诈发行证券案需调取公司有关证据材料。截至目前，案件处于公安 机关侦查阶段，尚未有明确结论。公司将积极配合调查取证工作，并根据案件进展履行信息披露义务。(格隆汇) ...

思创医惠(300078.SZ)盘初一度跌逾15%，现跌10.33%报3.56元，总市值不足40亿元。思创医惠公告称， 公司于2025年8月14日收到杭州市公安局出具的《调取证据通知书》，《调取证据通知书》显示，杭州 市公安局侦办的公司等涉嫌欺诈发行证券案需调取公司有关证据材料。截至目前，案件处于公安机关侦 查阶段，尚未有明确结论。公司将积极配合调查取证工作，并根据案件进展履行信息披露义务。 ...

Core Viewpoint - Sichuang Medical (300078) experienced a significant drop of 15.62% at the opening, with a share price of 3.35 yuan due to a legal issue involving allegations of fraudulent securities issuance [1] Company Summary - Sichuang Medical received a notification from the Hangzhou Public Security Bureau requesting evidence related to an investigation into alleged fraudulent securities issuance [1]

Policy Developments - The National Healthcare Security Administration (NHSA) has issued the "Interim Measures for the Management of Disease-Specific Payment" to promote a multi-faceted healthcare payment reform focused on disease-specific payments [1][2] - The framework consists of eight chapters and thirty-nine articles, emphasizing budget management, grouping scheme formulation, and core elements and supporting measures [2][3] - The introduction of this measure is expected to enhance the standardization of disease-specific payment systems and improve the efficiency of healthcare fund utilization [3] Drug and Medical Device Approvals - Kehua Bio's syphilis antibody quality control product has received a medical device registration certificate, which will enhance the company's product line [4] - Haikang Pharmaceutical's new indication application for HSK39297 tablets has been accepted, targeting age-related macular degeneration and generalized myasthenia gravis [5] Financial Reports - Leksin Medical reported a revenue of 521 million yuan for the first half of the year, a year-on-year increase of 4.57%, with a net profit of 42.29 million yuan, up 21.35% [6] - Gilead Sciences reported a revenue of 104 million yuan for the first half of the year, a significant increase of 111.4%, with a net loss of 87.95 million yuan, narrowing by 32.5% [7] Mergers and Acquisitions - Yunnan Baiyao plans to acquire 100% equity of Juyitang Pharmaceutical for 660 million yuan to enhance its business layout and expand its market presence [8] - Kangzhong Medical intends to invest 20 million yuan to acquire a 6.67% stake in Shanghai Renyan Information Technology to support its strategic transformation [9] Industry Events - Ji Xunming has been appointed as the president of the Chinese Academy of Medical Sciences and Peking Union Medical College [10] - The National Health Commission and the Ministry of Education are urging Beijing Union Medical College to rectify issues related to its "4+4" pilot program [11] Other Developments - Buchang Pharmaceutical's subsidiary plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine for 15 million yuan [12] - Zhongke Investment plans to reduce its stake in Nanwei Medical by up to 2% due to funding needs [13] - Sichuan Medical Technology has received a notice from the Hangzhou Public Security Bureau regarding evidence collection related to a securities fraud investigation [14]

Policy Developments - The National Healthcare Security Administration (NHSA) has issued the "Interim Measures for the Management of Disease-Specific Payment in Medical Security" to promote a multi-faceted payment reform focused on disease-specific payments [2] - The measures consist of eight chapters and thirty-nine articles, emphasizing budget management, grouping scheme formulation, and core elements and supporting measures [2][3] - The new regulations aim to enhance the scientific level of medical insurance payments and standardize the payment process [2] Drug and Device Approvals - Kehua Bio's syphilis antibody quality control product has received a medical device registration certificate, which will enhance the company's product line [5] - Haikang's new indication application for HSK39297 tablets has been accepted, targeting age-related macular degeneration and myasthenia gravis, indicating potential for effective treatment [6] Financial Reports - Leksin Medical reported a revenue of 521 million yuan for the first half of the year, a year-on-year increase of 4.57%, with a net profit of 42.29 million yuan, up 21.35% [8] - Gilead Sciences reported a revenue of 104 million yuan for the first half of the year, a significant increase of 111.4%, with a net loss of 87.95 million yuan, narrowing by 32.5% [9] Capital Market Activities - Yunnan Baiyao plans to acquire 100% of the equity of Juyitang for 660 million yuan to enhance its business layout and expand its market presence [11] - Kangzhong Medical intends to invest 20 million yuan to acquire a 6.67% stake in Shanghai Renyan Information Technology to support its strategic transformation [12] Industry Events - Ji Xunming has been appointed as the president of the Chinese Academy of Medical Sciences and Peking Union Medical College, indicating a leadership change in a key medical institution [14] - The National Health Commission and the Ministry of Education are urging Beijing Union Medical College to rectify issues related to its "4+4" pilot program, focusing on stricter management and oversight [15] Public Sentiment Alerts - Zhongke Investment plans to reduce its stake in Nanwei Medical by up to 2%, indicating potential changes in shareholder structure [18] - Sichuan Medical received a notice from the Hangzhou Public Security Bureau regarding evidence collection related to a fraud investigation, highlighting ongoing legal scrutiny [20]

Core Viewpoint - The company, Sichuang Medical (300078), is currently under investigation by the Hangzhou Public Security Bureau for alleged fraudulent issuance of securities, with the case still in the investigation stage and no clear conclusion reached yet [1]. Financial and Regulatory Summary - The Zhejiang Securities Regulatory Commission previously found that Sichuang Medical inflated its revenue and profits through its wholly-owned subsidiary, resulting in a cumulative inflated revenue of 34.93 million yuan and inflated profits of 33.02 million yuan in 2019, which accounted for 20.03% of the total profit for that period [1]. - For the period from January to September 2020, the company inflated its revenue by 60.96 million yuan and profits by 52.37 million yuan, representing 56.81% of the total profit for that period [1]. - The company was fined 85.7 million yuan and its former chairman was fined 7.5 million yuan and banned from the market for 10 years due to serious violations of securities laws [3]. - In 2024, Sichuang Medical reported revenues of 691 million yuan but incurred a net loss of 502 million yuan, which was a 42.64% reduction in losses compared to the previous year [4]. - In the first quarter of 2025, the company reported a net loss of 19.56 million yuan, further narrowing the loss compared to 67.77 million yuan in the same period last year [4]. Corporate Restructuring and Business Focus - Following the regulatory penalties, the company underwent significant changes in its ownership structure and business focus, including the resignation of its former chairman and the sale of its subsidiary, Medical Technology, for 300 million yuan [3]. - The company has shifted its focus towards Internet of Things (IoT) business after divesting its smart medical business [3]. - To alleviate cash flow pressure, the company sold two properties in 2024 and reported improved cash flow and increased bank credit [4].

Core Viewpoint - The company Sichuan Medical Technology Co., Ltd. (思创医惠) is under criminal investigation for financial fraud, following previous administrative penalties related to falsified financial statements [1][4][5]. Group 1: Investigation and Legal Actions - The company received a notification from the Hangzhou Public Security Bureau regarding the collection of evidence related to a fraud case involving securities issuance [1][4]. - The investigation focuses on past financial data and is linked to an earlier administrative penalty issued by the Zhejiang Securities Regulatory Commission [3][5]. - The Zhejiang Securities Regulatory Commission found that the company inflated its revenue by CNY 34.93 million and profits by CNY 33.02 million in 2019, which constituted 20.03% of the total profit for that period [6][7]. Group 2: Financial Performance and Adjustments - In 2024, the company reported a revenue of CNY 690.77 million, a decrease of 31.33% compared to 2023, and a net loss of CNY 501.51 million, which is a 42.64% reduction in losses year-on-year [11][12]. - The company has undergone significant restructuring, including the resignation of its former chairman and the sale of its subsidiary, which was the main platform for the financial fraud [9][10]. - The company is shifting its focus from smart medical services to the Internet of Things (IoT) business, aiming to enhance its growth engine [10]. Group 3: Investor Relations and Future Plans - The company is actively communicating with investors regarding potential compensation plans and is coordinating with courts on specific details related to investor lawsuits [8]. - A strategic cooperation framework has been established with the Cangnan County government to support various aspects of business development [9].